MetabolicIn Clinical Trials

Glepaglutide

Subcutaneous injection

Overview

Glepaglutide is a long-acting GLP-2 receptor agonist peptide developed for the treatment of short bowel syndrome. GLP-2 promotes intestinal growth, enhances nutrient and fluid absorption, and reduces gastric secretion, thereby improving intestinal function in patients with compromised bowel length.

Mechanism of Action

The compound is administered subcutaneously to sustain therapeutic effects over extended intervals..

Research Summary & Key Findings

Phase 3 trials in adults with short bowel syndrome have demonstrated reductions in the volume of parenteral support required, with results published in gastroenterology journals in 2020 and 2021. The safety profile was generally favorable, with injection-site reactions and gastrointestinal symptoms being most common. Regulatory submissions are under consideration in multiple regions.

Clinical Status

In Clinical Trials

Glepaglutide is currently undergoing clinical trials. It is not yet FDA-approved and is available only through clinical research settings or investigational protocols.

Administration Routes

Subcutaneous injection

Related Peptides in Metabolic

Semaglutide (Ozempic/Wegovy)

FDA Approved

A glucagon-like peptide-1 receptor agonist (GLP-1 RA) with 94% amino acid homology to native GLP-1. Semaglutide enhances...

View details

Tirzepatide (Mounjaro/Zepbound)

FDA Approved

A first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. Tirzepatide activat...

View details

Retatrutide

In Clinical Trials

An investigational triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. The gluc...

View details

AOD-9604

Investigational

A modified 16-amino acid fragment (amino acids 176-191) of the C-terminus of human growth hormone with an added tyrosine...

View details

Find a Provider

Find a verified provider who offers Glepaglutide therapy in your area.

Browse Provider Map

Find a Pharmacy

Browse PCAB-accredited and FDA 503B-registered compounding pharmacies that supply Glepaglutide.

Pharmacy Directory

Join the Association

Access exclusive peptide protocols, provider resources, and community support.

List Your Practice

Disclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol.